EGFR and neoplasm: Elevated expression of PD-L1 on tumour cells is frequently secondary to induction by TILs [163], or driven by driver mutations [164], e.g., mutations in epidermal growth factor receptor (EGFR), via signalling through the PI3K-AKT-STAT3/mTOR pathway, hindering activation of TILs [165].